Pfizer bails on Irish pension overhaul after workers union rejection

Pfizer Little Island plant Ireland
Workers at Pfizer's Little Island plant, which will make the move with Upjohn's Mylan merger, agreed to support the pension overhaul. (Pfizer)

Pfizer and some of its Irish plant workers have been locked in a yearslong battle over switching pensions from a rare no-contribution scheme to one in which employees pay toward their retirement. Nearly a year after plant unions threatened to strike over the feud, Pfizer has agreed to scuttle the overhaul.

Pfizer has ended negotiations with 700 workers at its Ringaskiddy plant to enact a direct-contribution pension plan that would require workers to pay into their retirement accounts––moving away from a so-called "direct benefit" plan that is an anomaly in private enterprise. 

Pfizer's exit followed the Ringaskiddy union's recent rejection of an Irish Workforce Relations Committee plan that would have provided for lump sum payments for retirees as well as giving employees an option to stay on their current plan with some contributions still required, according to the Irish Times. 

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

The 200 workers at Pfizer's Little Island plant, who previously held out on the agreement, had agreed to sign on to the committee's plan, the Times reported. An additional 100 Dublin workers are on Pfizer's direct benefit plans. 

RELATED: Pfizer braces for work stoppage after announcing it will switch the pensions of Irish holdouts

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.